Concepts (53)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 8 | 2024 | 935 | 2.740 |
Why?
|
| Quercetin | 5 | 2024 | 45 | 2.170 |
Why?
|
| Lignans | 3 | 2024 | 21 | 2.120 |
Why?
|
| Furans | 3 | 2024 | 38 | 2.090 |
Why?
|
| Tea | 4 | 2024 | 45 | 1.720 |
Why?
|
| Antineoplastic Agents | 3 | 2022 | 803 | 1.070 |
Why?
|
| Taxoids | 2 | 2016 | 37 | 1.040 |
Why?
|
| Tumor Burden | 2 | 2020 | 77 | 0.840 |
Why?
|
| Receptors, CCR2 | 1 | 2020 | 26 | 0.730 |
Why?
|
| Cell Proliferation | 5 | 2020 | 1198 | 0.710 |
Why?
|
| Chemokine CCL2 | 1 | 2020 | 85 | 0.680 |
Why?
|
| Adipose Tissue | 1 | 2020 | 177 | 0.640 |
Why?
|
| Inflammation | 1 | 2020 | 618 | 0.520 |
Why?
|
| Cell Line, Tumor | 5 | 2020 | 2231 | 0.420 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 259 | 0.400 |
Why?
|
| Obesity | 1 | 2020 | 1067 | 0.400 |
Why?
|
| Receptors, Androgen | 3 | 2020 | 126 | 0.390 |
Why?
|
| Drug Synergism | 3 | 2016 | 177 | 0.370 |
Why?
|
| Prostate | 2 | 2024 | 154 | 0.370 |
Why?
|
| Chemoprevention | 2 | 2024 | 35 | 0.350 |
Why?
|
| Male | 8 | 2024 | 20025 | 0.350 |
Why?
|
| Mice | 4 | 2024 | 5913 | 0.310 |
Why?
|
| Animals | 6 | 2024 | 15081 | 0.280 |
Why?
|
| Apoptosis | 3 | 2022 | 1398 | 0.260 |
Why?
|
| Mice, SCID | 2 | 2016 | 150 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 1039 | 0.240 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2024 | 54 | 0.230 |
Why?
|
| Hormones | 1 | 2022 | 55 | 0.210 |
Why?
|
| Neovascularization, Pathologic | 1 | 2022 | 127 | 0.200 |
Why?
|
| Humans | 7 | 2022 | 37093 | 0.190 |
Why?
|
| Mice, Knockout | 1 | 2024 | 933 | 0.190 |
Why?
|
| Exosomes | 1 | 2022 | 101 | 0.180 |
Why?
|
| Adipokines | 1 | 2020 | 24 | 0.180 |
Why?
|
| Adipocytes | 1 | 2020 | 58 | 0.170 |
Why?
|
| Administration, Oral | 1 | 2020 | 224 | 0.170 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 132 | 0.170 |
Why?
|
| Cytokines | 1 | 2020 | 602 | 0.140 |
Why?
|
| Transcription Factors | 1 | 2020 | 681 | 0.120 |
Why?
|
| Catechin | 1 | 2015 | 31 | 0.120 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 1371 | 0.120 |
Why?
|
| Androgens | 1 | 2014 | 89 | 0.120 |
Why?
|
| MicroRNAs | 2 | 2022 | 426 | 0.120 |
Why?
|
| STAT3 Transcription Factor | 1 | 2014 | 90 | 0.120 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2013 | 12 | 0.120 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2013 | 48 | 0.110 |
Why?
|
| Plant Extracts | 1 | 2016 | 286 | 0.110 |
Why?
|
| Down-Regulation | 1 | 2015 | 435 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 269 | 0.110 |
Why?
|
| Neoplasms | 1 | 2022 | 1103 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 807 | 0.090 |
Why?
|
| Signal Transduction | 1 | 2014 | 1908 | 0.070 |
Why?
|
| Ligands | 1 | 2022 | 349 | 0.050 |
Why?
|
| Models, Biological | 1 | 2022 | 677 | 0.040 |
Why?
|